News | April 26, 2024
Merck 1Q 2024 sales up 9% to US$ 15.8 billion
Sales reflect continued strong growth in oncology and vaccines
Sales reflect continued strong growth in oncology and vaccines
Open a printable version of this pageEmail the URL of this page to a friend
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Subscribe To Our Newsletter & Stay Updated
